Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE:000403)
China flag China · Delayed Price · Currency is CNY
13.49
-0.15 (-1.10%)
Feb 13, 2026, 3:04 PM CST

SHE:000403 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Jan '23 Jan '22 Jan '21
Operating Revenue
2,3822,6542,3252,3961,9661,042
Other Revenue
1.051.053.279.595.277.44
2,3832,6552,3292,4051,9721,050
Revenue Growth (YoY)
-16.23%14.00%-3.18%21.98%87.80%14.67%
Cost of Revenue
1,2851,3521,1301,1511,064537.36
Gross Profit
1,0981,3031,1991,254907.93512.58
Selling, General & Admin
435.11437.26465.81565.05419276.16
Research & Development
40.1155.1879.6975.3635.6311
Other Operating Expenses
27.6622.0721.6916.815.282.52
Operating Expenses
500.79509.9565.15666.86477.73285.99
Operating Income
596.86793.13633.7587.01430.2226.59
Interest Expense
-15.79-10.67-9.63-12.03-10.78-19.31
Interest & Investment Income
60.578.0175.0868.2262.318.31
Currency Exchange Gain (Loss)
0.130.13-0.122.4-0.21-
Other Non Operating Income (Expenses)
19.280.030.64-2.23-3.44-3.67
EBT Excluding Unusual Items
660.99860.61699.67643.37478.06221.92
Impairment of Goodwill
-----103.18-
Gain (Loss) on Sale of Investments
11.176.38-18.974.9374.21-
Gain (Loss) on Sale of Assets
-0.04-0.12-0.540.440.270.02
Asset Writedown
-4.68-3.46-1.29-3.59-0.49-5.27
Legal Settlements
-----2.14-
Other Unusual Items
-27.49-10.879.2515.2411.280.52
Pretax Income
640.17852.78688.11660.39458.01217.19
Income Tax Expense
80.39107.7476.6472.766.4734.51
Earnings From Continuing Operations
559.78745.04611.47587.69391.54182.68
Minority Interest in Earnings
-0.010.280.64-0.56-0.483.28
Net Income
559.77745.32612.11587.13391.06185.97
Net Income to Common
559.77745.32612.11587.13391.06185.97
Net Income Growth
-32.45%21.76%4.25%50.14%110.29%15.90%
Shares Outstanding (Basic)
941950947950917637
Shares Outstanding (Diluted)
941950947950919637
Shares Change (YoY)
-0.80%0.28%-0.33%3.38%44.25%0.21%
EPS (Basic)
0.600.780.650.620.430.29
EPS (Diluted)
0.600.780.650.620.430.29
EPS Growth
-31.91%21.42%4.60%45.23%45.78%15.66%
Free Cash Flow
-477.22-198.92301.74145.5882.06154.66
Free Cash Flow Per Share
-0.51-0.210.320.150.090.24
Dividend Per Share
0.2690.3850.1540.0620.043-
Dividend Growth
-150.06%149.27%43.16%--
Gross Margin
46.07%49.08%51.48%52.13%46.05%48.82%
Operating Margin
25.05%29.88%27.21%24.41%21.82%21.58%
Profit Margin
23.49%28.08%26.28%24.41%19.83%17.71%
Free Cash Flow Margin
-20.03%-7.49%12.96%6.05%4.16%14.73%
EBITDA
705.51913.93770.71704.63538.01273.96
EBITDA Margin
29.61%34.43%33.10%29.30%27.29%26.09%
D&A For EBITDA
108.64120.8137.02117.62107.8247.37
EBIT
596.86793.13633.7587.01430.2226.59
EBIT Margin
25.05%29.88%27.21%24.41%21.82%21.58%
Effective Tax Rate
12.56%12.63%11.14%11.01%14.51%15.89%
Revenue as Reported
2,3832,6552,3292,4051,9721,050
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.